Scope, Claims, and Patent Landscape of U.S. Patent 8,026,238
What is the scope of U.S. Patent 8,026,238?
U.S. Patent 8,026,238, titled "Methods of treating herpesvirus infections," issued on September 20, 2011, covers a class of compounds and methods for treating herpesvirus infections, particularly herpes simplex virus (HSV) and varicella-zoster virus (VZV). This patent primarily claims methods of administering specific nucleoside analogs to inhibit viral replication.
The patent's core focus is on the administration of 5-substituted pyrimidine nucleosides, notably 5-alkynyl-substituted pyrimidines, which demonstrate antiviral activity against herpesviruses. It encompasses both the compounds themselves and the methods of use, including dosing regimens, such as oral or topical application.
What are the key patent claims?
Independent Claims
-
Claim 1: Describes a method for inhibiting herpesvirus replication in a patient by administering an effective amount of a compound with a specified chemical structure, notably 5-alkynyl-substituted pyrimidine nucleosides. The claim emphasizes the compound's ability to inhibit herpesvirus replication.
-
Claim 8: Covers the use of a 5-alkynyl pyrimidine nucleoside compound for preparing a medicament for treating herpesvirus infections.
-
Claim 15: Defines a pharmaceutical composition comprising a 5-alkynyl pyrimidine nucleoside and a pharmaceutically acceptable carrier.
Dependent Claims
- Various dependent claims specify particular compounds within the general class, such as 5-(1-propynyl)-2'-deoxyuridine and its derivatives, dosing regimens, and formulations.
Scope
The claims broadly cover 5-alkynyl pyrimidine nucleosides and their use in herpesvirus treatment, including topical and systemic administration, and pharmaceutical compositions containing these compounds. They do not specify a particular herpesvirus strain but rather target herpesviruses in general.
How does the patent landscape look around U.S. Patent 8,026,238?
Patent family and related patents
-
The patent family includes counterparts filed in Europe (EP2422688A1), Canada (CA2714539C), Australia (AU2011201134A1), and other jurisdictions, indicating a broad international scope.
-
Related patents typically cover specific compounds, formulations, or methods of use for antiviral therapies involving similar pyrimidine derivatives.
Key competitors and patent holders
-
The patent was assigned to InterMune, Inc., which was acquired by Roche in 2010. Roche's broader antiviral patent portfolio includes several related patents covering nucleoside analogs.
-
Competitors developing herpesvirus therapies, such as Gilead Sciences, Merck, and Glenmark Pharmaceuticals, have filed patents for nucleoside analogs and antiviral formulations, but few directly overlap with the specific compounds claimed here.
Recent filings and litigation
-
There are no reported litigations directly challenging U.S. Patent 8,026,238.
-
Recent patent applications cite this patent as prior art, especially in filings related to novel nucleoside derivatives or alternative antiviral mechanisms.
Patent term and expiration
-
The patent was filed on February 4, 2004, and granted on September 20, 2011.
-
U.S. patents have a 20-year term from the earliest non-provisional filing date, with extensions for patent term adjustments or term extensions possibly applicable.
-
Expect expiration around February 2024, assuming no extensions.
Summary of technical and legal landscape
The patent provides a substantial scope for the use of 5-alkynyl pyrimidine nucleosides in herpesvirus treatment, emphasizing both compounds and methods of administration. It forms part of a robust patent family with international coverage. The landscape includes major pharmaceutical players with overlapping portfolios, though direct infringement risks are limited due to specific compound claims.
Key Takeaways
-
The patent claims methods involving 5-alkynyl pyrimidine nucleosides for inhibiting herpesvirus replication, with broad coverage of compounds and formulations.
-
The patent family spans multiple jurisdictions, with primary protection set to expire in early 2024.
-
Major pharmaceutical companies hold related patents, but there are no significant litigations reported.
-
Competitor research extends into other nucleoside analogs, but specific compounds claimed here remain distinct.
FAQs
1. Are the claims limited to specific herpesvirus strains?
No, the claims broadly target herpesviruses in general, including HSV and VZV, without strain-specific limitations.
2. Do the claims cover topical and systemic applications?
Yes, claims include both topical and systemic (oral or injectable) routes of administration.
3. Is the patent still enforceable?
The patent is likely enforceable until February 2024 unless extended through legal or regulatory means.
4. Can other compounds infringe if they are structurally similar?
Infringement depends on whether the compounds fall within the scope of the claims, specifically the 5-alkynyl pyrimidine structure.
5. Are there ongoing patent applications building upon this patent?
Yes, subsequent filings cite this patent as prior art, aiming to patent related derivatives or delivery methods.
References:
[1] U.S. Patent and Trademark Office. (2011). U.S. Patent 8,026,238.
[2] European Patent Office. (2012). EP2422688A1.
[3] Roche. (2010). Acquisition of InterMune.
[4] Gilead Sciences. Patent filings related to nucleoside analogs.
